| __timestamp | Halozyme Therapeutics, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79696000 | 94231000 |
| Thursday, January 1, 2015 | 93236000 | 146394000 |
| Friday, January 1, 2016 | 150842000 | 188272000 |
| Sunday, January 1, 2017 | 150643000 | 166707000 |
| Monday, January 1, 2018 | 150252000 | 401843000 |
| Tuesday, January 1, 2019 | 140804000 | 560909000 |
| Wednesday, January 1, 2020 | 34236000 | 722343000 |
| Friday, January 1, 2021 | 35672000 | 771182000 |
| Saturday, January 1, 2022 | 66607000 | 877090000 |
| Sunday, January 1, 2023 | 76363000 | 877387000 |
| Monday, January 1, 2024 | 79048000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Sarepta Therapeutics, Inc. and Halozyme Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Sarepta Therapeutics has consistently increased its R&D budget, with a remarkable 830% growth, peaking in 2023. This surge underscores their aggressive pursuit of cutting-edge therapies. In contrast, Halozyme Therapeutics experienced a more fluctuating R&D expenditure, with a notable dip in 2020, followed by a gradual recovery.
Sarepta's strategy reflects a robust focus on expanding its therapeutic pipeline, while Halozyme's approach suggests a more cautious allocation of resources. As the biotech landscape evolves, these spending patterns offer valuable insights into each company's long-term vision and potential impact on healthcare innovation.
Bristol-Myers Squibb Company vs Sarepta Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
United Therapeutics Corporation or Sarepta Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: United Therapeutics Corporation vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Analyzing R&D Budgets: Sarepta Therapeutics, Inc. vs ImmunityBio, Inc.
Sarepta Therapeutics, Inc. or Agios Pharmaceuticals, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Jazz Pharmaceuticals plc vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and MorphoSys AG
R&D Spending Showdown: Halozyme Therapeutics, Inc. vs Viridian Therapeutics, Inc.